The clinical-stage Clene Nanomedicine Firm Reported Significantly Decreased Mortality in Amyotrophic Lateral Sclerosis (ALS)
CNM-Au8® treatment resulted in a significant survival benefit (5 CNM-Au8 deaths vs 14 placebo deaths
CNM-Au8 treatment was well-tolerated, with no significant safety findings during this trial
Clene Inc in the NEWS
Clene Inc (CLNN), along with its subsidiaries, “Clene”, and its wholly owned . . .